<DOC>
	<DOC>NCT02834884</DOC>
	<brief_summary>SPECTArare is a program aiming at establishing a quality assured platform for collecting clinicopathologically annotated biological material from patients with primary rare tumors (6 new cases/100,000/year) to support biospecimen-based translational research and biomarker discovery.</brief_summary>
	<brief_title>SPECTArare: Screening Patients With Rare Tumors for Efficient Clinical Trial Access</brief_title>
	<detailed_description />
	<criteria>Patients with pathologically confirmed rare tumor types Mandatory availability of adequate human biological material (HBM): at least one FFPE tissue sample from either the primary tumor and/or recurrent tumor and/or metastasis, obtained from any adequate surgery or biopsy Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening; Minimal dataset of demographic, clinicopathological and treatment data to be recorded; Age â‰¥ 16 years; Written informed consent according to ICH/GCP and national/local regulations;</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rare cancer</keyword>
	<keyword>biomarker</keyword>
	<keyword>screening</keyword>
</DOC>